Previous 10 | Next 10 |
home / stock / aplif / aplif news
Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmace...
Appili Therapeutics ( OTCQB:APLIF ) said that it will get a patent from the U.S. Patent and Trademark Office (USPTO) for ATI-1501, a liquid oral reformulation of the antibiotic metronidazole. Metronidazole is used to treat parasitic and anaerobic bacterial infections. T...
Anticipated new patent strengthens ATI-1501’s potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market. Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharma...
Appili Therapeutics ( OTCQX:APLIF ) has announced that the U.S. Department of Defense will provide at least $14M in funding over two years to fund the development of ATI-1701. ATI-1701 is a potential first-in-class vaccine candidate for the prevention of infection with aerosol...
Dr. Armand Balboni appointed as Chair of the Board and moves to the U.S. Air Force Academy to take over as Principal Investigator for the ATI-1701 program; and Dr. Don Cilla promoted to President and Chief Executive Officer of Appili Appili Therapeutics Inc. (TSX: APLI; OTCQ...
Appili Therapeutics press release ( OTCQX:APLIF ): Q2 GAAP EPS of -C$0.04. As of September 30, 2022, the Company had cash of C$2.4 million, compared to C$6.7 million on March 31, 2022. For further details see: Appili Therapeutics GAAP EPS of -C$0.04
Appili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501, a liquid oral formulation of the antibiotic metronidazole. ...
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders hel...
Appili Therapeutics press release ( OTCQX:APLIF ): Q1 GAAP EPS of -$0.03 misses by $0.01 . As of June 30, 2022, the Company had cash and short-term investments of $5.55 million, compared to $6.66 million on March 31, 2022. For further details see: Appili Therapeu...
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its f...
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
Appili Therapeutics Inc Website:
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...